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key role for monocyte-derived macrophages for the
evelopment, progression, and destabilization of atheroscle-
otic plaques has long been recognized. However, the scale
f relatively focal macrophage activity in the plaque changes
ramatically after atherothrombotic complications. While
ocal proliferation ensures renewal and maintenance of
any macrophage cardiac pools under steady-state condi-
ions, prolonged acute ischemia and tissue injury in myo-
ardial infarction (MI) attracts massive amounts of mono-
ytes from circulation. The biological aim of this response is
o promote healing of the damaged myocardial tissue by the
emoval of dead cells, replacement of necrotic areas by
onnective tissue, remodeling of myocardial structure and
eometry to compensate cardiomyocyte loss, and ultimately,
o restore cardiac vascularization, at least at a microvascular
evel. Indeed, circulating monocytes and their tissue descen-
ents, the macrophages, produce myriad cytokines orches-
rating various processes of myocardial repair (1,2). How-
ver, an imbalance in this process may result in unfavorable
emodeling with the development of cardiac impairment,
ventually leading to heart failure in some patients despite a
uccessful and prompt restoration of blood flow by coronary
ntervention (3).
See page 130
onocyte populations. Circulating monocytes are not
niform and include subsets with profoundly different
haracteristics. At present, monocyte populations are com-
only described on the basis of the expression of the
ipopolysaccharide receptor CD14 and Fc receptor III
CD16). Although the differential monocyte populations
ay have implications for the pathogenesis of atherosclero-
is, it is not yet clear how they may do so, for example, by
ifferent expression of lipoprotein scavenger receptors
nd/or inflammatory characteristics.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.d
From the Haemostasis, Thrombosis and Vascular Biology Unit, University De-
artment of Medicine, City Hospital, Birmingham, United Kingdom.Amajor subset (85%) of large, high-density CD14CD16
onocytes co-expressing CD64 represent potent phago-
ytes, and produce large amounts of proinflammatory cyto-
ines (for example, interleukin-1, interleukin-6), reactive
xygen species, and prostaglandin E2 (4). In addition,
D14CD16 monocytes are active producers of plasmin-
gen activator (5).
In contrast, a smaller (15%) subset of smaller, less dense
D16 (usually CD14low) monocytes produces more
nterferon- and exhibits potent antigen-presenting capac-
ty. Despite lower expression of CD14, the expression of
oll-like receptor-4 (an essential coreceptor for CD14) is
.5-fold higher on CD14lowCD16 monocytes, which are
ighly active in the production of tumor necrosis factor 
nd interleukin-12 (6).
In addition to the CD14CD16 and CD14lowCD16
onocyte populations described in the preceding text, there
s a monocyte population (5% of all monocytes) that is
oth CD14 and CD16. These CD14CD16 mono-
ytes can be mobilized in a catecholamine-dependent man-
er, with a 4-fold increase in quantity after intensive
hysical exercise (7). However, physically active subjects
ave a lower percentage of CD14CD16 monocytes,
hich is associated with levels of tumor necrosis factor 
8). The CD14CD16 monocyte counts positively corre-
ate with levels of atherogenic lipids and negatively correlate
ith high-density lipoprotein cholesterol levels (9). Patients
ith coronary artery disease have higher numbers of
D14CD16 monocytes than do healthy subjects (10).
f note, the patients with the highest proportion (namely,
pper quartile) of CD14CD16 monocytes have an odds
atio of 4.9 (95% confidence interval: 2.5 to 19.1) for
oronary artery disease, even after adjusting for other con-
ounding factors such as diabetes mellitus, hypertension,
nd lipid profile (10).
onocyte populations in myocardial infarction. As
ighlighted in this issue of the Journal, Tsujioka et al. (11)
emonstrated specific dynamics of monocyte subsets after
resentation with an acute myocardial infarction (AMI).
hey found that the magnitude of CD14CD16 mono-
yte mobilization was associated with a marker of cardiac
ecovery (myocardial salvage), but CD14CD16 counts
ad no impact on cardiac recovery, and the biological role of
he observed dynamics of their number remains unclear.
urther insight into the role of monocyte subsets in MI may
e possible by putting the observations of Tsujioka et al.
11) in the context of previous experimental findings.
In an experimental study, Nahrendorf et al. (12) revealed
hat circulating levels of Ly-6Chi cells (a mouse analogue of
D14CD16 monocytes) closely corresponded to their
yocardial levels, which constituted 78% of myocardial
onocytes and macrophages early after MI onset. This
onocyte subset was shown to exhibit phagocytic, proteo-
ytic, and inflammatory properties, as well as being able to
igest necrotic myocardium (12). Similarly, Tsujioka et al.
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Monocyte Diversity in Myocardial Infarction July 7, 2009:139–4211) demonstrated high and exclusive expression of the
onocyte chemoattractant protein (MCP)-1 receptor
CR2 by the CD14CD16 monocytes. Importantly,
lasma MCP-1 levels are known to increase as early as 3 h
fter the onset of chest pain, and reach their maximum at
4 h, with further gradual decline (13). Putting together the
linical data on such early secretion of MCP-1 and the
rompt up-regulation of CCR-2 expressing CD14CD16
onocytes—as demonstrated by Tsujioka et al. (11)—with
ther experimental evidence that cardiac mobilization of
hese cells closely depends on cardiac MCP-1 synthesis and
ecretion, we can perhaps improve our understanding of the
athophysiological role of MCP-1 in regulation and mono-
ytosis during the early phase of MI.
However, does this monocyte population have any sig-
ificance beyond phagocytosis of damaged myocardium?
nterestingly, MCP-1 contributes to the development of
oronary collaterals during the early phase of AMI and
xperimental MCP-1–stimulated neovascularization, inde-
endently from bone marrow endothelial progenitor cell
nvolvement. Such interactions may indicate a possible link
etween MCP-1–dependent CD14CD16 monocyte
obilization and myocardial angiogenesis (14,15). Indeed,
uman monocytes include a population of cells able to
Figure 1 Expression of Type 1 Receptor to VEGF on Monocyte
Expression of type 1 receptor to vascular endothelial growth factor (VEGF) on mon
CD14lowCD16 monocytes (c). APC  allophycocyanin; FITC  fluorescein isothio
growth factor receptor.btain an endothelial cell phenotype in culture, and these
robably constitute a major population of circulating endo-
helial progenitors and cells expressing vascular endothelial
rowth factor receptors (VEGFR2) (16–18). Additionally,
onocyte-derived progenitors are able to successfully re-
tore left ventricular function after experimental MI, and
he number of circulating CD14/VEGFR2 cells is sig-
ificantly increased in AMI (19,20). We have also observed
hat one-third of CD14CD16 monocyte express recep-
ors to VEGF (VEGFR1), compared to only 8% of
D14lowCD16 monocytes and in contrast to the ex-
remely high expression (up to 90%) of VEGFR1 by a
ubset of CD14highCD16 monocytes (Fig. 1).
Nonetheless, MCP-1 levels determined during admission
f 2,270 patients with acute coronary syndrome who were
nrolled in the OPUS–TIMI 16 (Orbofiban in Patients
ith Unstable Coronary Syndromes–Thrombolysis In
yocardial Infarction 16) trial (21) were independently
ssociated with an increased risk of death or MI during 10
onths of follow-up, perhaps indicating that an unbalanced
CP-1 overexpression may have a negative impact on the
ecruitment of proinflammatory CD14CD16 mono-
ytes, thus resulting in impaired myocardial recovery—
hich has essentially been confirmed by Tsujioka et al. (11).
lations
opulations: CD14CD16 monocytes (a); CD14CD16 monocytes (b), and
e; PE  phycoerythrin; SSC  sideward scatter; VEGFR  vascular endothelialPopu
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July 7, 2009:139–42 Monocyte Diversity in Myocardial InfarctionIn contrast to CD14CD16 monocytes, Tsujioka et al.
11) found that the increase in the number of CD14CD16
ells was delayed and was not associated with any marker of
ardiac outcome. Of note, given the initial decrease in the
umber of circulating CD16 cells (as compared with stable
oronary artery disease), it appears that the consequent
ncrease in their levels might simply reflect a return to the
nitial count. Similarly, in an experimental model of MI, no
ignificant changes in the circulating levels of Ly-6Clo
mouse analogues CD14CD16 monocytes) were ob-
erved. Despite this, the number of CD14CD16 mono-
ytes in the myocardium increases dramatically in the
econd phase of MI, and these cells are recruited de novo
rom the circulation, constituting 80% of myocardial
onocytes and macrophages (12). Furthermore, Nahren-
orf et al. (12) have shown that although circulating levels
ere not affected, their capacity to migrate into myocardium
ncreased 4.8-fold. These data, therefore, indicate that a
imple count of CD14CD16 monocytes in the circula-
ion may not accurately reflect their cardiac activity, and
dditional changes in functional characteristics (e.g., recep-
or expression) and/or high levels of certain cytokines/
hemoattractants may be responsible for their selective
obilizations.
Interestingly, CD14CD16 monocytes fail to migrate
n response to CCL2 in vitro, consistent with the absence of
CP-1 receptors on these cells (22), as demonstrated by
sujioka et al. (11). However, CD14CD16 monocytes
xclusively express fractalkine receptor CX3CR1, and frac-
alkine levels reportedy decrease only in the early phase of
I and are restored by the time of active CD14CD16
onocyte recruitment (12,23). Although CX3CR1 was
ssential for CD16 monocyte homing, this receptor alone
annot explain the enhanced selective migration of CD16
onocytes, as it is equally expressed (strongly) on cells both
n the stable situation (namely, in healthy controls) and in
isease (MI), thus indicating that other receptors should
imultaneously be involved in this process. Indeed,
D14CD16 monocytes show enhanced expression of
CR5 and stromal cell derived factor (SDF)-1 receptors
XCR4, as well as a high migratory activity in response to
DF-1 and macrophage inflammatory protein-1a/
ANTES (22,24).
Although the role of CD14CD16 monocytes in MI
emains obscure, mouse analogues of these cells have proan-
iogenic properties and selectively express higher levels of
EGF, a well-recognized potent regulator of angiogenesis
12). Expression of receptors for proangiogenic SDF-1 may
lso be of similar importance (25,26). In a mouse experi-
ental model, macrophage colony-stimulating factor re-
uces the infarct area and improves left ventricular remod-
ling after MI, through the recruitment of CXCR4 cells
nto the infarcted myocardium (26).
These important findings may serve as a basis to provide
ome explanation for one of the existing monocyte-related
ontroversies, that is, monocytes are required for successfulyocardial recovery—but monocytosis and high levels of
CP-1 may be associated with negative outcomes. This
ontroversy may stem from the excessive (or prolonged)
ecretion of monocyte chemoattractants and abnormal
onocyte recruitment into myocardium, thus causing an
mbalance in the reparative and negative monocyte proper-
ies. Clearly, further studies are warranted to better under-
tand the monocyte role in post-MI myocardial recovery.
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ity Hospital NHS Trust, University Department of Medicine,
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